A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of the American College of Cardiology

• Publication date

  1999-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0735-1097(99)00107-2PMID 10362188
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator

  2004cited by this paper
• Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.

  1997cited by this paper
• Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO)

  1997cited by this paper
• Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.

  1996cited by this paper
• Inhibition by Argatroban, a Specific Thrombin Inhibitor, of Platelet Activation by Fibrin Clot-associated Thrombin

  1996cited by this paper
• TIMI frame count: a quantitative method of assessing coronary artery flow.

  1996cited by this paper
• A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.

  1996cited by this paper
• Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.

  1995influential reference
• Blood coagulation. The thrombin paradox.

  1995cited by this paper
• The thrombin paradox

  1995cited by this paper
• Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.

  1994cited by this paper
• Effects of the Synthetic Thrombin Inhibitor Argatroban on Fibrin- or Clot-Incorporated Thrombin: Comparison with Heparin and Recombinant Hirudin

  1994cited by this paper
• Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.

  1994cited by this paper
• Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.

  1994cited by this paper
• Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

  1994cited by this paper
• Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.

  1994cited by this paper
• An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

  1993cited by this paper
• The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

  1993cited by this paper
• Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)

  1992cited by this paper
• Persistent inhibition of arterial thrombosis by a 1‐hour intravenous infusion of argatroban, a selective thrombin inhibitor

  1992cited by this paper
• Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction.

  1991cited by this paper
• A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.

  1990cited by this paper
• Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.

  1990cited by this paper
• Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.

  1990cited by this paper
• In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.

  1990cited by this paper
• Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.

  1990cited by this paper
• Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?

  1989cited by this paper
• Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid.

  1984cited by this paper

• Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review

  2022cites this paper
• Anticoagulation Management during Extracorporeal Membrane Oxygenation—A Mini-Review

  2022cites this paper
• Development of a carotid artery thrombolysis stroke model in mice

  2022cites this paper
• Direct thrombin inhibitors and factor Xa inhibitors for acute coronary syndromes: a network meta-analysis

  2022cites this paper
• Antithrombin and Its Role in Host Defense and Inflammation

  2021cites this paper
• A Prospective Pilot Trial to Assess the Efficacy of Argatroban (Argatra®) in Critically Ill Patients with Heparin Resistance †

  2020cites this paper
• Bivalirudin during thrombolysis with catheter‐directed tPA in a heparin‐refractory patient: A case report

  2019cites this paper
• Safety and Feasibility of using Argatroban immediately after mechanical thrombectomy for large artery occlusion.

  2019cites this paper
• JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome.

  2019cites this paper
• Argatroban plus aspirin versus aspirin in acute ischemic stroke

  2018cites this paper
• Parenteral Anticoagulants: Direct Thrombin Inhibitors and Pentasaccharides

  2018cites this paper
• Combining Intravenous Thrombolysis and Antithrombotic Agents in Stroke: An Update

  2018cites this paper
• Update in the Early Management and Reperfusion Strategies of Patients with Acute Ischemic Stroke

  2018cites this paper
• Response by Barreto and Grotta to Letter Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".

  2017cites this paper
• Progrediente Dyspnoe nach Implantation einer Edwards-Sapien-3-Bioprothese

  2016cites this paper
• Changing Management of Acute Ischaemic Stroke: the New Treatments and Emerging Role of Endovascular Therapy

  2016cites this paper
• Treatment and Prevention of Heparin-Induced Thrombocytopenia Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2015cites this paper
• Recent Advances in Optimal Adjunctive Antithrombotic Therapy in STEMI Patients Undergoing Primary Angioplasty: An Overview.

  2015cites this paper
• Imaging of prehospital stroke therapeutics

  2015cites this paper
• Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future

  2015cites this paper
• Advances in Medical Revascularisation Treatments in Acute Ischemic Stroke

  2014cites this paper
• Combining antithrombotic and fibrinolytic agents: can it be done?

  2013cites this paper
• Catheter-directed Thrombolysis with Argatroban and tPA for Massive Iliac and Femoropopliteal Vein Thrombosis

  2013cites this paper
• 26 – Antithrombotic Agents

  2013cites this paper
• Adjunctive and Alternative Approaches to Current Reperfusion Therapy

  2012cites this paper
• Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome

  2012influential citation
• Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia

  2012cites this paper
• Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• The Argatroban and tPA Stroke Study: final results of a pilot safety study

  2012cites this paper
• The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.

  2012cites this paper
• Prevention of Venous Thromboembolism Following Orthopaedic Surgery

  2012cites this paper
• Ancillary approaches to plasminogen activators

  2012cites this paper
• Tarek Ahmed bw.indd

  2011cites this paper
• Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises

  2011cites this paper
• The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials.

  2010cites this paper
• Direct Thrombin Inhibitors in Acute Coronary Syndromes

  2010cites this paper
• Antithrombotic drug therapy in cardiovascular disease

  2010cites this paper
• Combination Pharmacotherapy for Achievement and Maintenance of Vascular Patency

  2009cites this paper
• Thrombosis and Hemostasis

  2009cites this paper
• Influence of antithrombin and argatroban on disseminated intravascular coagulation parameters in a patient with septic shock.

  2009cites this paper
• Progress in Neurotherapeutics and Neuropsychopharmacology: The Argatroban and tPA Stroke Study

  2008cites this paper
• Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction

  2008cites this paper
• Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease

  2008cites this paper
• Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII

  2008cites this paper
• Anticoagulants in coronary artery disease.

  2008cites this paper
• Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Anticoagulants Coronary Ar tery Disease

  2008cites this paper
• Clinical Practice Guidelines ( 8 th Edition ) College of Chest Physicians Evidence-Based and Thrombolytic Treatment : American Hemorrhagic Complications of Anticoagulant

  2008cites this paper
• Direct Antithrombins

  2007cites this paper
• Direct thrombin inhibitors in cardiac disease

  2007influential citation
• Recent advances in serine protease inhibitors as anticoagulant agents.

  2007cites this paper
• Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation

  2007cites this paper
• The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT

  2007cites this paper
• Heparin-induced thrombocytopenia II-induced critical limb ischaemia treated with urokinase and argatroban

  2007cites this paper
• Argatroban: update.

  2006cites this paper
• Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions.

  2006cites this paper
• Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives

  2006cites this paper
• Platelet Activity, Coagulation, and Fibrinolysis During Exercise in Healthy Males: Effects of Thrombin Inhibition by Argatroban and Enoxaparin

  2006cites this paper
• Argatroban tPA stroke study: study design and results in the first treated cohort.

  2006cites this paper
• Treatment of heparin-induced thrombocytopenia in cardiovascular patients

  2006cites this paper
• Argatroban

  2006cites this paper
• Present and Future Anticoagulants

  2006cites this paper
• The direct thrombin inhibitors: their role and use for rational anticoagulation.

  2005cites this paper
• Overview of contemporary reperfusion strategies in acute ST-elevation myocardial infarction

  2005cites this paper
• Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor

  2005cites this paper
• Management of Acute Myocardial Infarction

  2005cites this paper
• Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents

  2005cites this paper
• Anticoagulant Use in Patients with Chronic Renal Impairment

  2005cites this paper
• Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin.

  2005influential citation
• Direct thrombin inhibitors for the treatment of acute coronary syndromes and during percutaneous coronary interventions.

  2005cites this paper
• © 2003 Ö‚ÓÔÂÈÒÍÓ ӷ˘ÂÒÚ‚Ó Í‡‰ËÓÎÓ"Ó‚. ĉ‡ÔÚËÓ‚‡ÌÌ˚È Ô‚Ӊ Ò ‡Ì"ÎËÈÒÍÓ"Ó flÁ˚͇ Ë ÚˇÊËÓ‚‡ÌËÂ

  2005cites this paper
• Anticoagulant and antiplatelet agents: their clinical and device application(s) together with usages to engineer surfaces.

  2004cites this paper
• [Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction].

  2004cites this paper
• Acute Ischemic Stroke Successfully Treated Using Sequenced Intravenous and Intra-Arterial Thrombolysis and Argatroban Anticoagulation: A Case Study

  2004cites this paper
• Direct Thrombin Inhibitors for Anticoagulation

  2004cites this paper
• Argatroban

  2004cites this paper
• Argatroban Anticoagulation in Conjunction with Glycoprotein IIb/IIIa Inhibition in Patients Undergoing Percutaneous Coronary Intervention: An Open-Label, Nonrandomized Pilot Study

  2004cites this paper
• Late ventricular potentials in risk assessment of the occurrence of complex ventricular arrhythmia in patients with myocardial infarction and heart failure.

  2004cites this paper
• A Synopsis of the Clinical Uses of Argatroban

  2004influential citation
• Antithrombin Therapy in Acute Coronary Syndromes

  2004cites this paper
• Clinician Update: Direct Thrombin Inhibitors in Acute Coronary Syndromes

  2003cites this paper
• HIT/HITT and alternative anticoagulation: current concepts.

  2003cites this paper
• The evolving role of direct thrombin inhibitors in acute coronary syndromes.

  2003cites this paper
• Antiplatelet and Anticoagulant Therapy

  2003cites this paper
• Anticoagulation in acute cardiac care in patients with chronic kidney disease.

  2003cites this paper
• An Overview of the Direct Thrombin Inhibitor Argatroban

  2003cites this paper
• Argatroban in HIT Type II and Acute Coronary Syndrome

  2003cites this paper
• Direct thrombin inhibitor therapy in the cardiovascular patient.

  2003cites this paper
• Managing heparin-induced thrombocytopenia: preventing life- and limb-threatening thrombosis. Introduction.

  2003cites this paper
• Overview of heparin-induced thrombocytopenia.

  2003cites this paper
• Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model.

  2003cites this paper
• Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.

  2003cites this paper
• Biomedical Research and Then Some: The Causes of Technological Change in Heart Attack Treatment

  2003cites this paper
• Management of Acute Coronary Syndromes

  2003cites this paper
• Management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology

  2002cites this paper
• [New anthithrombotic drugs].

  2002cites this paper
• Treatment of Heparin-Induced Thrombocytopenia

  2002cites this paper
• Selective Inhibition of Coagulation Factors: Advances in Antithrombotic Therapy

  2002cites this paper
• Lack of pharmacokinetic interactions between argatroban and warfarin.

  2002cites this paper
• Comparison of two different methods of quantitative coronary angiography in patients with acute coronary syndromes

  2002cites this paper